TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04776447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Structure: The cis-diamino (cyclobutane-1, 1 dicarboxylate) plating. Stability: 24 hours at ambient temperature in 5% glucose, glucosamine or physiologic saline. It is recommended not to dilute with chlorinated solutions for this could affect the carboplatin.~Route of administration: Intravenous infusion.~Guidelines of Carboplatin administration: According to the standard of each center.~Other Name: ATC code: L01XA02

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placlitaxel
Description: Structure: A diterpene whose composition is: 5b, 20-epoxy-1, 2a, 4,7b, 10b, 13a-hexahidroxytax-11-en 9 one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)- N-benzoyl-3-phenylisoserine.~Stability: Concentrations of 0.3-1.2 mg/ml in 5% dextrose or normal saline have demonstrated chemical and physical stability for more than 27 hours at ambient temperature (25ºC approximately). The intact vial must be stored between 15º and 25ºC.~Guidelines of Paclitaxel administration: Paclitaxel must be administered by infusion over 3 hours in dextrose (D5W) or normal saline (NS). The concentration must not exceed 1.2 mg/ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is a humanized immunoglobulin (IgG1) monoclonal antibody that is produced in Chinese hamster ovary (CHO) cells. Atezolizumab targets programmed death-ligand 1 (PD-L1) on tumor-infiltrating immune cells (ICs) or tumor cells (TCs) and prevents interaction with the programmed death-1 (PD-1) receptor and B7.1 (CD80), both of which function as inhibitory receptors expressed on T cells and other immune cells.~Patients will receive 1200 mg of atezolizumab administered by IV infusion every 21 days (+/- 3 days) in a monitored setting where there is immediate access to trained personnel and adequate equipment/medicine to manage potentially serious reactions.
Study: NCT06350240

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: An exercise program that can be easily applied at home and in the park, which will support the psychomotor, tactile and proprioceptive-rich sensory development specific to children with joint hypermobility. The family will be instructed to do these exercises for 30 minutes a day for 5 days in total, 2 days a week in the playground and 3 days at home for 6 weeks, and the family will be asked to keep a diary to see whether they do the exercises or not.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise+texture insoles
Description: In addition to exercise, children in this group will have an individual textured insoles made to suit the child's foot. The child will be asked to place textured insoles inside his shoes and use the textured insoles for 6-8 hours.
Study: NCT05374057

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chiropractic spinal manipulative therapy (CSMT)
Description: See study arm.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: CSMT sham manipulation
Description: See study arm.
Study: NCT04842682

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Combi 3 group
Description: CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 3.0 and 1.0 mg/injection, i.e. 1.2 ml subcutaneous route in right deltoid; and combined with DNA at 4.0 mg/injection, i.e. 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24~Or, NaCl at 0.9%, i.e 1.2 ml subcutaneous route in right deltoid and 1 ml intramuscular route in left deltoid at weeks 0, 4 and 24.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Late boost CD40 alone
Description: CD40.HIVRI.Env at 0.3 mg/injection, i.e. 1 ml subcutaneous route in right deltoid at week LB (late boost)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Late boost CD40 adjuvanted
Description: CD40.HIVRI.Env and Poly-ICLC (Hiltonol), respectively at 0.3 and 1.0 mg/injection, i.e. 1 ml subcutaneous route in right deltoid at week LB (late boost)
Study: NCT06578455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) Powder
Description: 66.68 mg CBD per capsule for a total of 400 mg CBD per serving

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) Powder
Description: 66.68 mg CBD per capsule for a total of 400 mg CBD per serving

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol 100 MG/ML [Epidiolex]
Description: 100 mg CBD/mL for a total of 400 mg CBD per serving

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabidiol 100 MG/ML [Epidiolex]
Description: 100 mg CBD/mL for a total of 400 mg CBD per serving
Study: NCT05088694

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peaceful Coexistence
Description: The Peaceful Coexistence intervention seeks to target important risk and protective factors related to tolerance and acceptance.~The Anti-Extremism intervention seeks to take the same risk and protective factors covered in the Peaceful Coexistence intervention and have students' psychosocial factors shift their skills and behavior.
Study: NCT05389332

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hispanics Skin Cancer intervention
Description: With the insights from the community, the investigators will then develop the mobile intervention targeting Hispanics at risk for skin cancer to promote sun protection and SSE and get feedback to optimize the intervention. After the random allocation participants will receive instructions on how to use WhatsApp and then the intervention. They will receive WhatsApp messages about skin cancer for three months with optimal frequencies determined by prior aims and complete a post-intervention survey which contains the same questions in the pre-survey. The pilot RCT will be conducted around the spring/summer of Year four of the R00 when UVR is generally the highest in the US. The participants will be contacted at six months after the baseline survey to complete another survey similar to the post-intervention survey.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group: physical activity and nutrition for Hispanics
Description: Content will be developed from established websites such as CDC's Division of Nutrition, Physical Activity and Obesity. We selected these topics because they are also of concern among Hispanics and provide an unrelated attention control.
Study: NCT06358872

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin for Oral Suspension
Description: Azithromycin will be administered as a single dose, in oral suspension form for children. The dose will be calculated by age or height depending on the child's age Both dosing cups and syringes will be used to administer treatment. For children too young to drink out of a dosing cup, a 1 ml or 5 ml syringe will be used, and the calculated dose will be rounded upwards to the nearest 0.2 ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin for Oral Suspension
Description: Azithromycin will be administered as a single dose, in oral suspension form for children. The dose will be calculated by age or height depending on the child's age Both dosing cups and syringes will be used to administer treatment. For children too young to drink out of a dosing cup, a 1 ml or 5 ml syringe will be used, and the calculated dose will be rounded upwards to the nearest 0.2 ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin for Oral Suspension
Description: Azithromycin will be administered as a single dose, in oral suspension form for children. The dose will be calculated by age or height depending on the child's age Both dosing cups and syringes will be used to administer treatment. For children too young to drink out of a dosing cup, a 1 ml or 5 ml syringe will be used, and the calculated dose will be rounded upwards to the nearest 0.2 ml.
Study: NCT04633252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: For mCSPC patients, prednisone is optional and if given, should be taken orally, at 5 mg once a day. For mCRPC patients, prednisone should be taken orally either, at 5mg twice a day for each dose or 10 mg once a day as is the patient s preference.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: For mCSPC patients, prednisone is optional and if given, should be taken orally, at 5 mg once a day. For mCRPC patients, prednisone should be taken orally either, at 5mg twice a day for each dose or 10 mg once a day as is the patient s preference.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: For mCSPC patients, prednisone is optional and if given, should be taken orally, at 5 mg once a day. For mCRPC patients, prednisone should be taken orally either, at 5mg twice a day for each dose or 10 mg once a day as is the patient s preference.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: For mCSPC patients, prednisone is optional and if given, should be taken orally, at 5 mg once a day. For mCRPC patients, prednisone should be taken orally either, at 5mg twice a day for each dose or 10 mg once a day as is the patient s preference.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824
Description: M7824 (2400 mg) will be administered as a 1 hour intravenous (IV) infusion once every three weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75mg/m\^2 will be administered intravenously every 21 days (i.e., a 3-week cycle) for up to 6 cycles in mCSPC and until progression or unacceptable toxicity in mCRPC.
Study: NCT05124678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoniazid Tablets
Description: High dose of isoniazid
Study: NCT06469268

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epro software
Description: EPRO software：patients with symptoms will fill in report forms via the software, when the data upload to the terminal, the doctor according to the results of the upload ePRO corresponding medical assessment,and give advises.
Study: NCT05523739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STI-1558
Description: An oral small molecule prodrug that effectively inhibits the SARS-CoV-2 main protease (Mpro).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STI-1558
Description: An oral small molecule prodrug that effectively inhibits the SARS-CoV-2 main protease (Mpro).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STI-1558
Description: An oral small molecule prodrug that effectively inhibits the SARS-CoV-2 main protease (Mpro).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STI-1558
Description: An oral small molecule prodrug that effectively inhibits the SARS-CoV-2 main protease (Mpro).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STI-1558
Description: An oral small molecule prodrug that effectively inhibits the SARS-CoV-2 main protease (Mpro).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STI-1558
Description: An oral small molecule prodrug that effectively inhibits the SARS-CoV-2 main protease (Mpro).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STI-1558
Description: An oral small molecule prodrug that effectively inhibits the SARS-CoV-2 main protease (Mpro).
Study: NCT05406895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% Lidocaine with 1:100,000 epinephrine
Description: 2% Lidocaine with 1:100,000 epinephrine will be used for administering the lower jaw anesthesia (inferior alveolar nerve block).
Study: NCT04633252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75mg/m\^2 will be administered intravenously every 21 days (i.e., a 3-week cycle) for up to 6 cycles in mCSPC and until progression or unacceptable toxicity in mCRPC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75mg/m\^2 will be administered intravenously every 21 days (i.e., a 3-week cycle) for up to 6 cycles in mCSPC and until progression or unacceptable toxicity in mCRPC.
Study: NCT05406895

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% Lidocaine with 1:100,000 epinephrine
Description: 2% Lidocaine with 1:100,000 epinephrine will be used for administering the lower jaw anesthesia (inferior alveolar nerve block).
Study: NCT04914663

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Exercise training performed at home under remote live supervision over 12 weeks while patients undergo chemotherapy for breast cancer.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Exercise training performed at home under remote live supervision over 12 weeks while patients undergo chemotherapy for breast cancer.
Study: NCT04633252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75mg/m\^2 will be administered intravenously every 21 days (i.e., a 3-week cycle) for up to 6 cycles in mCSPC and until progression or unacceptable toxicity in mCRPC.
Study: NCT04837040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paltusotine
Description: Paltusotine, tablets, once daily by mouth

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, tablets, once daily by mouth
Study: NCT05098288

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicentre Pain Monitor + Unified Protocol
Description: The intervention will consist in a self-applied online transdiagnostic intervention for emotional problems together with an app-based EMA. In terms of monitoring, the Multicentre Pain Monitor is a mobile app whose contents have been adapted to conduct ecological momentary assessments in different health conditions. The app assesses important psychological variables, namely anxiety, depressive symptoms,etc. Participants respond daily to the questions in the app. In terms of the online self-applied intervention, the Unified Protocol is a transdiagnostic extension of CBT which works on regulate emotions in a more adaptive way through 5 core treatment modules: present-focused emotional awareness, cognitive flexibility, identification and prevention of emotional avoidance patterns, increasing awareness and tolerance to emotion-elicited physical sensations, and graded (interoceptive and situational) exposure procedures.
Study: NCT04956484

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belimumab
Description: Belimumab 10 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Steroid(≤1mg/kg/d) with or without proper immunosuppressants：CTX, MMF, AZA, CsA, FK 506, HCQ, MTX, LEF, SASP etc.
Study: NCT05637450

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blue Whiting Protein Hydrolysate
Description: 25g Blue Whiting Protein Hydrolysates mixed with an everyday food / drink product daily for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Isocalorific maltodextrin citrus flavoured powder mixed with an everyday food / drink product for 6 weeks
Study: NCT06337409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Generic empagliflozin 25 mg film-coated tablets
Description: Empagliflozin 25 mg film-coated tablets
Study: NCT05346302

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pneumovax 23
Description: At +14 days from enrollment in the trial, participants will receive a vaccine administered via intramuscular route only.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Typhim VI
Description: At +14 days from enrollment in the trial, participants will receive a vaccine administered via intramuscular route only.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: At +14 days from enrollment in the trial, participants will receive a vaccine administered via intramuscular route only.
Study: NCT04633252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M9241
Description: M9241 at escalating doses and then at RP2D will be administered as a subcutaneous injection every three weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M9241
Description: M9241 at escalating doses and then at RP2D will be administered as a subcutaneous injection every three weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M9241
Description: M9241 at escalating doses and then at RP2D will be administered as a subcutaneous injection every three weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M9241
Description: M9241 at escalating doses and then at RP2D will be administered as a subcutaneous injection every three weeks.
Study: NCT04948619

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Vaccine
Description: Patients will have lab evaluations for immune function at baseline, 3, 6, 9 and 24 months post completion of treatment. At 3 months off therapy, patients with abnormal vaccine antibody titers will be randomized to receive either single booster vaccines or to begin a full revaccination series that models post-hematopoietic stem cell transplant vaccination strategies.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Vaccine
Description: Patients will have lab evaluations for immune function at baseline, 3, 6, 9 and 24 months post completion of treatment. At 3 months off therapy, patients with abnormal vaccine antibody titers will be randomized to receive either single booster vaccines or to begin a full revaccination series that models post-hematopoietic stem cell transplant vaccination strategies.
Study: NCT04710316

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 screening by molecular biology
Description: SARS-CoV-2 RT-PCR in nasopharyngeal swab targeting 2 regions of the viral genome

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 screening by molecular biology
Description: SARS-CoV-2 RT-PCR in nasopharyngeal swab targeting 2 regions of the viral genome

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Serological screening
Description: Serological screening of caregivers at D0, M1, M2, M3 (anti-nucleocapsid antibodies).
Study: NCT05856838

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NovaSure ablation
Description: Ablation of the endometrial tissue using the NovaSure device
Study: NCT06447207

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational Therapy Led Social Prescription
Description: The intervention includes encouragement to participate in the co-designed social prescription with 6 monthly sessions with an occupational therapist or occupational therapy doctoral student.
Study: NCT05086796

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Substance Use Treatment and Recovery Team (START)
Description: START is a model of care based on Collaborative Care. START is team driven, population-focused, measurement based, and focused on promoting adoption of evidence-based interventions. The purpose of this model is to increase adoption of evidence-based interventions for opioid use disorder and to increase linkage to aftercare.~The components of the START intervention are as follows:~1. Triage~2. Engage, Assess, and Plan~3. Treat~4. Communicate and Coordinate~5. Follow up~6. Monitor
Study: NCT05307692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seltorexant
Description: Seltorexant 20 mg will be administered orally as a tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered orally as a tablet.
Study: NCT05206773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venglustat (GZ402671)
Description: Pharmaceutical form: Tablet Route of administration: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Tablet Route of administration: Oral
Study: NCT05076513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: In Phase 0, 300mg administered orally QD for 4 days prior to resection.~In the Expansion cohort/Maintenance phase, niraparib will be administered as described below:~* For patients weighing \<77 kg (\<170 lbs) OR with a platelet count \<150,000/mcL, the recommended dosage is 200 mg taken orally once daily.~* For patients weighing ≥77 kg (≥170 lbs) AND a platelet count ≥150,000/ mcL, the recommended dosage is 300 mg taken orally once daily.
Study: NCT06337409

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Generic empagliflozin 25 mg film-coated tablets
Description: Empagliflozin 25 mg film-coated tablets
Study: NCT02215629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VS-4718
Study: NCT05529953

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oleanolic acid (CAS no. 598-02-1; PubChem CID 10494)
Description: Postprandial study of bioavailability of Oleanolic acid, formulated as functional olive oil, in healthy subjects

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control commercial olive oil
Description: Postprandial study of Oleanolic acid bioavailability in healthy subjects
Study: NCT05737498

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Description: Transcranial direct current stimulation will use to deliver a constant direct current through two surface electrodes, Anodal stimulation was applied according to the 10-20 international system for EEG electrode placement, over F3 of the dorsolateral prefrontal cortex (DLPFC), while the cathode was placed over the contralateral supraorbital area for 20 min, on alternate days for 2 weeks 6 sessions with working memory training task. the anode (positive) and the cathode (negative). To reduce resistance and minimize discomfort during application (the electrodes were covered in 35 cm2, saline-soaked sponges
Study: NCT04795362

Intervention type: BIOLOGICAL
Intervention: blood sample
Description: 5 tubes of 1 milliliters (ml) will be sampled on a catheter placed as part of the usual practice every hour for 4 hours (at Time 0, at Time 1 hour, at time 2hours, at Time 3 hours, at time 4 hours) as soon as DCI is suspected.~In the event of a mechanical angioplasty decision, the samples will be continued (Time 0, Time 2 hours, Time 4 hours, Time 6hours, Time 12 hours, Time 24 hours, so 6 samples of 1 ml).
Study: NCT05935488

Intervention type: OTHER
Intervention: EVOCs emulsion
Description: Continuous breath sampling directly into SIFT-MS equipment. The instrument is equipped with a mouthpiece connected to the SIFT inlet where the subject blows in and the breath is analyzed in real-time